Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Galapagos

Ionis Pharma

This year will probably go down as the roughest year for investors since the financial recession in 2008. The S&P 500 has shed more than 20% of its value year-to-date as inflation and interest rates weigh down the equities market.

3 Biotech Stocks to Sell in October

There is a high chance that the Illumina, Inc.-Grail deal would collapse after European regulators decide to block the acquisition. Without Grail, I believe Illumina will find it hard to maintain growth in light of disruptions in its end markets, namely the clinical gene testing sector.

Illumina Engages Obama To Push Its Customers' Reimbursement Agenda

Illumina Inc , the top maker of DNA sequencers used to speed drug development and other research, on Thursday announced the launch of its next-generation NovaSeq X systems, which it said can generate more than 20,000 whole genomes per year, or 2.5 times that of prior sequencers.

Illumina launches next-generation DNA sequencers

New technology enables highest levels of accuracy at immense scale, with the power to sequence more than 20,000 genomes per year Our most sustainable high-throughput sequencer delivers 90% reduction in packaging and 50% reduction in plastic waste, and eliminates dry ice shipments, expanding global access to genomic medicine SAN DIEGO , Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the NovaSeq™ X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing.

Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

SAN DIEGO , Sept. 26, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its inaugural Illumina Genomics Forum, being held in San Diego from September 28 through October 1, is sold out.

Illumina Genomics Forum Sold Out, Announces Opportunity to View Innovation Roadmap Session via Livestream

Manulife Financial

Highlights power of strategic industry partnerships to promote preventive health and empower well-being  BOSTON , Sept. 20, 2022 /PRNewswire/ -- Today, John Hancock , the US division of Toronto-based Manulife (NYSE: MFC), announced it is offering access to GRAIL's Galleri® multi-cancer early detection test to a pilot group of existing customers through the John Hancock Vitality Program, in collaboration with reinsurer Munich Re Life US.

John Hancock becomes the first life insurance carrier to offer access to GRAIL's multi-cancer early detection test to customers

SAN DIEGO , Sept. 19, 2022 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) will host its 2022 Investor Day on Monday, October 3 rd starting at 8:00am Pacific Time in San Diego, CA.

Illumina to Host Upcoming Investor Day

Speakers will discuss how genomics drives more informed, inclusive, and proactive care SAN DIEGO , Sept. 19, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel titled "Clinical Genomics Is Now.

Illumina Genomics Forum to Feature Nobel Laureate Frances Arnold as part of Distinguished Panel on How the Genomics Revolution Is Transforming Patient Care

The panel will generate ideas and inspiration to build the foundational elements needed to make genomic health equitable, informed, and accountable SAN DIEGO , Sept. 12, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel of leading visionaries, titled "Architecting Health's Radically New Infrastructure," as part of its inaugural Illumina Genomics Forum being held in San Diego from September 28 through October 1.

Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health's Radically New Infrastructure

MENLO PARK, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version. A multimedia asset accompanying this release and paragraph seven have been removed. The updated release reads: GRAIL ANNOUNCES FINAL RESULTS FROM THE PATHFINDER MULTI-CANCER EARLY DETECTION SCREENING STUDY AT ESMO CONGRESS 2022 Adding Multi-Cancer Early Detection (MCED) Screening to Standard of Care Screening More Than Doubled the Number of Cancers Detected 71% of Participants With MCED-Detecte

CORRECTING and REPLACING GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced final results from the interventional PATHFINDER study, which evaluated multi-cancer early detection (MCED) screening using a blood test and the clinical care pathways following a “cancer signal detected” MCED test result in 6,662 individuals aged 50 years or older, an age group at elevated risk for cancer. Results were presented in a proffered pape

GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022

Cross Country Healthcare

Regeneron Pharmaceuticals

With the exception of energy and utilities, all sectors of the S&P 500 are in the red for the year. Of the losing sectors, healthcare stocks have held up relatively well, outperformed only by consumer staples.

The 3 Best Healthcare Stocks to Buy Now

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL announced final results from the interventional PATHFINDER study will be presented at the European Society for Medical Oncology Congress 2022

GRAIL to Present Final Multi-cancer Early Detection Data From the Interventional PATHFINDER Study at ESMO Congress 2022

SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that investors, analysts, and other interested parties may view a live webcast of the Innovation Roadmap session of the Illumina Genomics Forum, which will be hosted by Francis deSouza, Chief Executive Officer, and Alex Aravanis, Chief Technology Officer.

llumina Announces Opportunity to View Live Webcast of Illumina Genomics Forum Innovation Roadmap Session Followed by Investor Conference Call

Full agenda now available for September 28–October 1 event SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the release of the full agenda for its inaugural Illumina Genomics Forum.

Illumina Genomics Forum to Feature Diverse Lineup of Visionary Global Leaders

Illumina announced Tuesday it plans to appeal the European Commission's decision to prohibit the company's acquisition of cancer detection company GRAIL.

Illumina to appeal after European Commission prohibits $7.1 billion GRAIL acquisition

Illumina stock jumped Tuesday after the EC blocked its acquisition of Grail — another step in a battle over the early cancer-detection outfit. The post Illumina Stock Pops After European Regulators Block $8 Billion Deal appeared first on Investor's Business Daily.

Illumina Stock Pops After European Regulators Block $8 Billion Deal

Block

The European Commission says Illumina's acquisition of Grail 'would have stifled innovation and reduced choice in the emerging market for blood-based early cancer detection tests.'

Illumina to Appeal European Commission Decision to Block Grail Acquisition

SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), today received a decision from the European Commission prohibiting the company's acquisition of GRAIL.

Illumina Intends to Appeal European Commission's Decision in GRAIL Deal

BRUSSELS (Reuters) -U.S. life sciences company Illumina is in talks with European Union antitrust regulators to divest Grail ahead of an expected EU veto next week of its $7.1 billion acquisition of the biotechnology company, people familiar with the matter said.

Exclusive-Illumina in talks with EU regulators to divest Grail - sources

The Federal Trade Commission on Friday filed a notice of appeal in its case challenging Illumina's $7.1 billion acquisition of cancer detection company GRAIL.

FTC appeals ruling in case challenging Illumina's acquisition of GRAIL

WASHINGTON (Reuters) -The Federal Trade Commission on Friday said it will appeal an administrative judge's decision earlier this week in favor of Illumina Inc's acquisition of cancer detection test maker Grail Inc, according to a spokesperson.

FTC to appeal judge's decision on Illumina-Grail deal

Source: Connect world / Shutterstock.com Genetic-sequence product specialist Illumina (NASDAQ: ILMN ) lit up business headlines on Thursday evening after the company secured a legal victory in an antitrust suit. Although ILMN stock bounced higher this morning, shares are now slipping about 2% in the Friday afternoon session.

Illumina (ILMN) Stock Rises After Its Win Against the FTC

Illumina's top line is going to be under more pressure in the short term as well as in the medium term.

Is Illumina a Buy?

Illumina is having a bumpy ride, but it's playing the long game.

News for Illumina Stock (ILMN)